The Supply Chain
From Synthesis to Doorstep
Four distinct supply chains bring peptides to market. Select a lane, then click any node on the map to see who's involved at that step and what actually happens.
Compounds in this lane
Drag to pan · scroll or use +/− to zoom · click any node to expand
Cross-Lane Comparison
What separates the four lanes
| Branded | 503A | 503B | Grey Market | |
|---|---|---|---|---|
| FDA Oversight | Full (NDA/BLA) | Partial (state boards) | CGMP inspections | None |
| Sterility Assurance | Validated GMP fill/finish | USP <797> cleanroom | CGMP ISO 5 | None / unverified |
| Potency Verification | Manufacturer QC release | COA from supplier | Full in-house QC | Optional / 3rd party |
| Prescription Required | Yes | Yes (patient-specific) | No (office use) | No |
| API Traceability | Full chain-of-custody | Registered supplier COA | Qualified supplier prog. | Minimal / variable |
| Endotoxin Testing | Mandatory | Required (USP <85>) | Mandatory per lot | Rarely performed |
| Cold-Chain Validation | Validated 3PL | Required for dispensing | Required for distribution | Inconsistent |
| Recall Capability | Lot-level, DSCSA tracked | Pharmacy-level | Lot-level | None |
| Legal Status (US) | Legal | Legal with valid Rx | Legal when compliant | Legally ambiguous |
| Cost to Patient | Highest | Moderate | Moderate-high | Lowest |
This page is an educational guide to how peptide supply chains are structured. It does not constitute legal advice, medical advice, or sourcing guidance. Regulatory landscapes change, particularly for compounded peptides subject to FDA shortage list determinations. Do your own research. Consult a licensed practitioner before use. Daily Peptide does not endorse, facilitate, or link to any commercial supply source.